Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11021
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrossmann, Mathisen
dc.contributor.authorGianatti, Emily Jen
dc.contributor.authorZajac, Jeffrey Den
dc.date.accessioned2015-05-16T00:36:00Z
dc.date.available2015-05-16T00:36:00Z
dc.date.issued2010-06-01en
dc.identifier.citationCurrent Opinion in Endocrinology, Diabetes, and Obesity; 17(3): 247-56en
dc.identifier.govdoc20418720en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11021en
dc.description.abstractTo describe the relationship between testosterone levels and type 2 diabetes (T2D).Multiple epidemiological studies have shown that low testosterone levels are associated with and predict the future development of T2D and the metabolic syndrome. Although this relationship is confounded by the association of total testosterone with sex hormone-binding globulin, free testosterone remains associated with measures of insulin resistance and T2D in some, but not all studies. Although the link between low testosterone levels and insulin resistance is not solely a consequence of adiposity, current studies suggest that a substantial component is mediated through its association with body fat, in particular abdominal visceral adipose tissue. This testosterone-fat relationship is bi-directional, as both weight loss and testosterone therapy increase testosterone levels, reduce fat mass, and decrease insulin resistance.Low testosterone levels are very commonly found in men with T2D and are associated with aging and obesity. Whether testosterone treatment in men with T2D decreases insulin resistance above that attributable to its fat-reducing effect is currently unknown. Future studies should compare testosterone treatment with lifestyle changes (exercise and weight loss measures), and other insulin-sensitizing agents. Until further evidence is available, testosterone therapy outside clinical trials should be reserved for diabetic men with unequivocal hypogonadism.en
dc.language.isoenen
dc.subject.otherAdiposity.physiologyen
dc.subject.otherAging.physiologyen
dc.subject.otherDiabetes Mellitus, Type 2.physiopathologyen
dc.subject.otherHumansen
dc.subject.otherInsulin Resistance.physiologyen
dc.subject.otherMaleen
dc.subject.otherMetabolic Syndrome X.physiopathologyen
dc.subject.otherSex Hormone-Binding Globulin.physiologyen
dc.subject.otherTestosterone.physiologyen
dc.titleTestosterone and type 2 diabetes.en
dc.typeJournal Articleen
dc.identifier.journaltitleCurrent opinion in endocrinology, diabetes, and obesityen
dc.identifier.affiliationDepartment of Medicine, Austin Health/Northern Health, University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1097/MED.0b013e32833919cfen
dc.description.pages247-56en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/20418720en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptEndocrinology-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Jan 30, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.